Owners, management and financials
CVR: 43055909
Previous names: Ouisa Pharma ApS
DKK -10,204,929
Gross profit
Net result: DKK -12,777,761
JLSa2 Therapeutics, Inc. (100%)
CVR · view owners
Anders Bue Klein, Christoffer Clemmensen
1 more in management
Board: Gaurav Gupta (chair) and 3 members
CVR · view management
Active
Founded 14 February 2022
CVR · view overview
8 employees
CVR · 2026
Owner registered: JLSa2 Therapeutics, Inc.
CVR · 31/07/2026
View the full event history
Ousia Pharma ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2022. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Ouisa Pharma ApS. The management consists of Anders Bue Klein, Christoffer Clemmensen and Jonas Odgaard Petersen. The board consists of Gaurav Gupta (chair), Menelas Nicolas Pangalos, Otello Stampacchia and Ramesh Rajanikant Bhatt. The company is owned by JLSa2 Therapeutics, Inc.. The company has 8 employees (2026). In 2025, the company reported a gross profit of DKK -10,204,929 and a net result of DKK -12,777,761 compared with DKK -5,348,579 the year before. Equity in the 2025 report amounted to DKK 11,818,220.
Formål er at udvikle nye lægemiddelkandidater til behandling af kroniske sygdomme.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | -10.2 mio. | -12.8 mio. | 12.5 mio. | 11.8 mio. | 8 | |
| 202401/01/2024 – 31/12/2024 | -3.7 mio. | -5.3 mio. | 5.1 mio. | -10.1 mio. | 6 | |
| 202301/01/2023 – 31/12/2023 | -2.2 mio. | -3.7 mio. | 5.8 mio. | -4.7 mio. | 5 | |
| 202214/02/2022 – 31/12/2022 | -645 t. | -904 t. | 3.3 mio. | -864 t. | 3 |
Compared to 1.039 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningThe CVR number of Ousia Pharma ApS is 43055909.
Ousia Pharma ApS is owned by JLSa2 Therapeutics, Inc..
The management of Ousia Pharma ApS consists of Anders Bue Klein, Christoffer Clemmensen and Jonas Odgaard Petersen.
The board of Ousia Pharma ApS consists of Gaurav Gupta, Menelas Nicolas Pangalos and Otello Stampacchia, with Gaurav Gupta as chair.
In 2025, Ousia Pharma ApS reported a gross profit of DKK -10,204,929.
Ousia Pharma ApS had 8 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
As of July 31, 2026, Gaurav Gupta has joined the board of directors of Ousia Pharma ApS.
As of July 31, 2026, Ramesh Rajanikant Bhatt has joined the board of directors of Ousia Pharma ApS.
As of July 31, 2026, Ian Rodney Laquian has left the board of directors of Ousia Pharma ApS.
As of July 31, 2026, Christoffer Clemmensen has left the board of directors of Ousia Pharma ApS.
As of July 31, 2026, Margareta Elisabeth Björk has left the board of directors of Ousia Pharma ApS.
As of July 31, 2026, is registered as an owner of Ousia Pharma ApS with an ownership share of 100%.
Ousia Pharma ApS has published its annual report for 2025. Gross profit came to DKK -10,204,929, and the net result was DKK -12,777,761.
Ousia Pharma ApS has published its annual report for 2024. Gross profit came to DKK -3,655,869, and the net result was DKK -5,348,579.
As of March 27, 2025, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Ousia Pharma ApS.
As of March 27, 2025, Menelas Nicolas Pangalos has joined the board of directors of Ousia Pharma ApS.
As of March 27, 2025, Otello Stampacchia has joined the board of directors of Ousia Pharma ApS.
As of March 27, 2025, Margareta Elisabeth Björk has joined the board of directors of Ousia Pharma ApS.
As of March 27, 2025, Mikael Søndergaard Thomsen has left the board of directors of Ousia Pharma ApS.
As of March 27, 2025, Jeppe Ragnar Andersen has left the board of directors of Ousia Pharma ApS.
As of March 27, 2025, Morten Peltola Toft has left the board of directors of Ousia Pharma ApS.
As of March 27, 2025, Jonas Odgaard Petersen has left the board of directors of Ousia Pharma ApS.
As of March 27, 2025, Anders Bue Klein has left the board of directors of Ousia Pharma ApS.
Ousia Pharma ApS has published its annual report for 2023. Gross profit came to DKK -2,239,754, and the net result was DKK -3,746,803.
Ousia Pharma ApS has published its interim report for the period February 14, 2022 to December 31, 2022.
As of February 14, 2023, Ian Rodney Laquian has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Mikael Søndergaard Thomsen has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Jeppe Ragnar Andersen has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Morten Peltola Toft has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Christoffer Clemmensen has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Jonas Odgaard Petersen has joined the board of directors of Ousia Pharma ApS.
As of February 14, 2023, Anders Bue Klein has joined the board of directors of Ousia Pharma ApS.
On February 22, 2022, the company changed its name from Ouisa Pharma ApS to Ousia Pharma ApS.
As of February 14, 2022, Christoffer Clemmensen is registered as director of Ousia Pharma ApS.
As of February 14, 2022, Jonas Odgaard Petersen is registered as director of Ousia Pharma ApS.
As of February 14, 2022, Anders Bue Klein is registered as director of Ousia Pharma ApS.
Ousia Pharma ApS was founded on February 14, 2022.
Uneven Bits ApS is an independent IT consultancy founded and operated by Klaus Byskov Pedersen. With deep expertise in software architecture and systems design, I help organizations build robust, scalable, and maintainable technical solutions. Whether you need strategic guidance on technology decisions, hands-on architecture work, or help navigating complex technical challenges, I bring focused expertise and a practical approach to every engagement.
Selskabets formål er IT- og kommunikationsvirksomhed samt virksomhed i øvrigt, der efter bestyrelsens skøn står i forbindelse hermed.
Selskabets formål er at udvikle, markedsføre, sælge og implementere software produkter til brug ved indkøbsstyring og dermed efter bestyrelsens skøn beslægtet virksomhed
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Companies in the same industry and area
CVR 46481585
CVR 36465972
CVR 45436497
CVR 46059220
CVR 46543912
